Dear members of the All.Can Belgium community,
I hope this message finds you in good health and spirits. I am thrilled to share some important news with you. After 38 fulfilling years and exciting work at Jules Bordet Institute and since 2017 as head of oncology Medicine Department, I will be embarking on a new chapter by accepting the roles of Head of Oncology Department for the entire site of CHIREC, and director of the CHIREC Cancer Institute from May 1st, 2024.
I want to assure you, first and foremost, that my commitment as the Chair of the Board for All.Can Belgium remains steadfast. If anything, this new responsibility will only deepen my dedication to our shared mission and goals.
One aspect of this new role that particularly excites me is the potential impact on patients within our community. Leading the oncology efforts for the entire site will allow me to contribute significantly to enhancing patient care, fostering innovation, and advancing research initiatives. I believe that my expanded role will not only benefit the hospital and Cancer Institute but will also create positive ripple effects for our non-profit organization.
I look forward to the opportunities that this new position will bring and the positive outcomes we can achieve together. My commitment to All.Can Belgium remains unwavering, and I am confident that this transition will, ultimately and foremost, enhance the support and resources we can provide to those who need it most – the patients in our community.
Thank you for your continued support, and I am eager to navigate this journey together for the betterment of our community.
Kind regards,
Prof. Ahmad Awada
Every year, almost 9,000 women [1] undergo a cone biopsy to treat precancerous lesions. Precancerous lesions are abnormal cells in the cervix that can develop into cervical cancer. They are detected through cervical screening. A cone biopsy is preceded by a colposcopy – a closer examination of the cervix. In…
Anal cancer is rare, almost always linked to HPV, and in many cases preventable — if we detect precancerous lesions in time. In an in-depth interview, Dr. Magali Surmont (UZ Brussels) shares how Belgium is taking action against anal cancer. She points to three key areas where we can truly…
Since January 2025, cervical cancer screening for women aged 30 and over has been carried out differently. The smear is now first tested for the presence of human papillomavirus (HPV), and only then, depending on the result of that first test, are the cells examined. There is a good reason…
